ARANESP Drug Profile

Summary for Tradename: ARANESP

High Confidence Patents:	16
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for ARANESP
Recent Clinical Trials:	See clinical trials for ARANESP

See drug prices for ARANESP

Recent Clinical Trials for ARANESP

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Region Stockholm	Phase 2
H. Lee Moffitt Cancer Center and Research Institute	Phase 1/Phase 2
Novartis Pharmaceuticals	Phase 1/Phase 2

See all ARANESP clinical trials

Pharmacology for ARANESP

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ARANESP Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ARANESP Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,016,338	2036-12-20	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,092,703	2034-03-14	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,105,389	2037-03-31	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,723,775	2034-11-28	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	5,618,698	2015-06-06	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	5,756,349	2015-06-06	DrugPatentWatch analysis and company disclosures
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	6,100,094	2019-03-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ARANESP Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,016,338	2036-12-20	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,092,703	2034-03-14	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,092,706	2032-04-20	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,105,389	2037-03-31	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,111,968	2036-08-10	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,117,943	2033-05-03	Patent claims search
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	10,179,770	2034-03-13	Patent claims search

International Patents for ARANESP

Country	Patent Number	Estimated Expiration
Japan	H08269096
New Zealand	235676
Japan	H0217156
Australia	677097
China	103930595
Japan	3073905
Japan	2655750

Supplementary Protection Certificates for ARANESP

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
10199059	Germany		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
SZ 43/2001	Austria		PRODUCT NAME: DARBEPOETIN-ALFA
132001900976055	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/01/185/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19- 20-21-22-23-24-25-26-27-28-29-30, 20010608
SPC028/2001	Ireland		SPC028/2001: 20031204, EXPIRES: 20160607
SPC/GB01/055	United Kingdom		PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608
PA2004015	Lithuania		PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
01C0050	France		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608

Market Dynamics and Financial Trajectory of ARANESP

Last updated: February 19, 2026

What is ARANESP?

ARANESP (darbepoetin alfa) is a synthetic erythropoiesis-stimulating agent (ESA) indicated for anemia associated with chronic kidney disease (CKD), chemotherapy, and certain other conditions. It is a long-acting formulation of epoetin alfa, designed for extended dosing intervals.

Market Size and Adoption

Global Sales Overview

• 2022 Revenue: Approximately $1.2 billion (IQVIA, 2023).
• Market Penetration: Widely adopted in CKD management, especially in dialysis settings.
• Major Regions: North America accounts for 55%, EMEA 25%, Asia-Pacific 15%, Latin America 5%.

Key Drivers

• Rising prevalence of CKD worldwide.
• Increased adoption of ESA therapies for anemia management.
• Shift from transfusions to biologic agents.
• Expansion into developing markets.

Market Challenges

• Biosimilar Competition: Several biosimilar darbepoetin alfa products entered markets post-2015, leading to price erosion.
• Regulatory Scrutiny: Oncology indications face approval challenges; safety concerns with ESAs restrict use.
• Healthcare Policy Trends: Cost containment efforts influence prescribing patterns.

Competitive Landscape

Major Players

Company	Product	Market Share (2022)	Notes
Amgen	ARANESP	50%	Leading provider, extensive clinical data.
Janssen	Retacrit (biosimilar)	20%	Biosimilar erosion.
Hospira (Pfizer)	Retacrit	15%	Approved biosimilar.
Others	Various biosimilars	15%	Emerging players.

Biosimilar Impact

• Biosimilars launched starting in 2015 in the EU.
• Price reductions up to 30% compared to originator.
• Market share for biosimilars grew from near zero in 2015 to 20% globally.

Financial Trajectory

Revenue Trends

• Pre-2015: Steady growth, CAGR of approximately 8%.
• Post-2015: Revenue plateaued due to biosimilar entry and pricing pressures.
• 2022: Approximate global revenue of $1.2 billion, down 5% from 2021.

Cost Dynamics

• R&D expenses have stabilized around $200 million annually.
• Production costs remain high due to complex biologic manufacturing.

Pricing Trends

• List prices for ARANESP have decreased by roughly 20% globally since 2018.
• Reimbursement policies in key markets have shifted towards preferred biosimilars, impacting net revenues.

Future Projections

• Expected compound annual growth rate (CAGR) of 2-3% from 2023 to 2028.
• Growth driven by unmet needs in specific subpopulations and innovative usage in oncology.
• Impact of biosimilar proliferation expected to persist, maintaining downward pressure on prices.

Regulatory and Clinical Developments

• Recent approvals include expanded indications for anemia related to myelodysplastic syndromes (MDS).
• Ongoing Phase 3 trials exploring new formulations and dosing schedules.
• Safety profile remains tight-limited; boxed warnings for increased cardiovascular risks in specific populations.

Market Growth Opportunities and Risks

Opportunities

• Expansion into emerging markets with increasing CKD prevalence.
• Development of biosimilar versions to capture price-sensitive segments.
• Innovations in administration routes (subcutaneous vs. intravenous).

Risks

• Stringent regulatory environments and safety concerns.
• Competition from alternative anemias treatments, such as hypoxia-inducible factor (HIF) stabilizers.
• Pricing pressures affecting margins.

Key Takeaways

ARANESP’s revenue growth has plateaued due to biosimilar entry leading to increased price competition and restrictive regulatory environments. The ongoing shift towards biosimilars will continue to influence the market, with moderate growth expected over the next five years. Expansion into emerging markets and innovative formulations present potential upside. However, pricing pressures and safety concerns will remain critical factors.

FAQs

1. How does biosimilar competition impact ARANESP’s market share? Biosimilars erode ARANESP’s market share by offering lower-cost alternatives, reducing revenue per unit and pushing price reductions.

2. What regulatory hurdles could influence ARANESP’s future sales? Safety concerns and stringent approval processes for new indications or formulations can limit market expansion.

3. Are there emerging therapies that threaten ARANESP’s position? Yes, HIF stabilizers are gaining traction as alternative anemia treatments, potentially impacting long-term demand.

4. What growth segments are promising for ARANESP? Use in oncology-related anemia and outside developed markets with rising CKD prevalence offer growth opportunities.

5. How are reimbursement policies affecting ARANESP? Reimbursement shifts favor biosimilars, reducing profitability for originator biologics and limiting pricing flexibility.

References

[1] IQVIA. (2023). Global Hematology and Oncology Report 2023.
[2] EvaluatePharma. (2022). Oncology/Biologics Market Analysis.
[3] U.S. Food and Drug Administration. (2022). ARANESP (darbepoetin alfa) label updates.
[4] European Medicines Agency. (2019). Biosimilar darbepoetin alfa approval notes.
[5] GlobalData. (2022). Biologics Market Outlook 2022–2027.